{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:43Z","timestamp":1786986883840,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clinthera.2019.10.005","type":"journal-article","created":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T09:56:02Z","timestamp":1572342962000},"page":"2540-2548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia"],"prefix":"10.1016","volume":"41","author":[{"given":"Tiffany M.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Juang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin H.","family":"Kollef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Betthauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.10.005_bib3","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2019.10.005_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12890-017-0552-x","article-title":"Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults","volume":"17","author":"Storms","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.clinthera.2019.10.005_bib5","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.3390\/vaccines6030059","article-title":"Relative clinical and cost burden of community-acquired pneumonia hospitalizations in older adults in the United States\u2014a cross-sectional analysis","volume":"6","author":"Olasupo","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.clinthera.2019.10.005_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12913-018-3529-4","article-title":"Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008\u20132014","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2019.10.005_bib7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.10.005_bib8","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2019.10.005_bib9","unstructured":"Biomerieux Inc. 2019. https:\/\/www.biofiredx.com\/products\/the-filmarray-panels\/filmarrayrp\/."},{"key":"10.1016\/j.clinthera.2019.10.005_bib10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.5858\/arpa.2014-0257-OA","article-title":"Impact of a rapid respiratory Panel test on patient outcomes","volume":"139","author":"Rogers","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clinthera.2019.10.005_bib11","series-title":"Poster presented at: The Clinical Virology Symposium, Daytona Beach, Florida","article-title":"Implementation of non-batched respiratory virus assay significantly impacts patient outcomes in the ICU","author":"Martinez","year":"2016"},{"key":"10.1016\/j.clinthera.2019.10.005_bib12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2019.10.005_bib13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"Martin-loeches","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2019.10.005_bib14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkp088","article-title":"Impact of intravenous {beta}-lactam\/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia","volume":"63","author":"Tessmer","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2019.10.005_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002898","article-title":"Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study","volume":"3","author":"Shorr","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2019.10.005_bib16","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2019.10.005_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcrc.2015.12.010","article-title":"Azithromycin use and outcomes in severe sepsis patients with and without pneumonia","volume":"32","author":"Afshar","year":"2016","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.clinthera.2019.10.005_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.95.08030398","article-title":"Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia","volume":"8","author":"Rizzato","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2019.10.005_bib19","first-page":"314","article-title":"De-escalation versus continuation of empirical antimicrobial therapy in community-acquired pneumonia","volume":"73","author":"Yamana","year":"2016","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.clinthera.2019.10.005_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2016.06.002","article-title":"Is de-escalation of antimicrobials effective? a systematic review and meta-analysis","volume":"49","author":"Ohji","year":"2016","journal-title":"Int J Infect Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:24Z","timestamp":1758963084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0149291819305016"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}